DMPK 3′ untranslated repeat expansions in unexplained sudden cardiac death in the young

Le résumé fourni par la source

Sudden cardiac death (SCD) is the unexpected death of a previously healthy individual due to a known or suspected cardiac cause. In our Australian/New Zealand SCD in the young (1–35 years) cohort, the annual incidence was ∼1.3 per 100 000.1 When no cause of SCD is found following comprehensive postmortem investigation, including toxicology and microbiology analysis, the case is classified as unexplained SCD. Causative variants in cardiac genes are identified in up to 27% of young unexplained SCDs, suggesting other causes exist.1 Myotonic dystrophy Type 1 (DM1) is an autosomal dominant, multisystemic disorder with a prevalence of 1:2100 births.2 The leading cause of mortality in DM1 is respiratory failure (38%), followed by sudden death (15%).3 Myotonic dystrophy Type 1 is caused by a CTG-repeat expansion in the 3′-untranslated region (3′UTR) of the DMPK gene. The age of onset and phenotype severity roughly correlate with repeat length: with 50–100 repeats associated with mild disease, ∼100–1000 with classic disease, and >1000 with congenital disease.4 Expanded [CUG]n DMPK transcripts cause mis-splicing of key cardiac transcripts, including SCN5A.5 Here, we describe three families with unexplained SCD in the young associated with DMPK 3’UTR-repeat expansions in the absence of overt neuromuscular features or evident conduction disease. Family-1 was enrolled in an unsolved inherited heart disease project and underwent short- and long-read genome sequencing. Triplet-primed polymerase chain reaction (TP-PCR)4 confirmed the DMPK 3′UTR-repeat expansion. Family-2 and Family-3 were identified from an Australian unexplained SCD cohort (n = 115, aged 1–35) with negative toxicology and microbiology analysis, who were prospectively recruited (2010–12)1 or recruited to the Genetic Heart Diseases Clinic at Royal Prince Alfred Hospital, Sydney (2014–24). Genetic testing and DMPK 3′UTR-repeat sizing were performed by genome sequencing (n = 58) or exome sequencing plus TP-PCR (n = 57) (AmplideX PCR/CE DMPK Kit, Asuragen). The female proband (II-2) had witnessed SCD during exercise at age 13; autopsy found no cause and a structurally normal 190 g heart. Her father had right ventricular (RV) abnormalities on cardiac magnetic resonance imaging (MRI) and left bundle branch block on electrocardiogram (ECG) (Figure 1A and B); the mother was clinically normal. Over the next decade, two siblings had witnessed SCD: II-5 during exercise at age 16 and II-3 after an argument at age 18. Autopsies showed normal hearts: II-3, with subtle subendocardial myocyte swelling and scattered contraction bands, suggesting subendocardial ischaemia, and II-5, 398 g heart with widespread contraction bands. Histology: RV not examined in any of the three unexplained SCDs; the left ventricle was normal. Two other siblings (II-1, II-4) received cardioverter-defibrillators. Sudden cardiac death individuals (II-3, II-5) had no conduction disease on ECG, exercise testing, or Holter; II-5 had prolonged corrected QT interval (QTc), and living sibling II-4 had abnormal RV. Long-read genome sequencing identified a heterozygous pathogenic DMPK 3′UTR-repeat expansion in II-3, II-5, and II-4. Retrospectively, the family reports that SCD child II-5 had slight clumsiness, and the father had early cataracts (before age 40). II-4 now has DM1 neurological features (Figure 1C). A heterozygous, likely paternally inherited MYL3 (c.235G > A;p.Val79Ile) variant of uncertain significance (VUS) was identified in II-3, II-4, and II-5 (Figure 1A) and was previously reported as a low-penetrance variant in a hypertrophic cardiomyopathy (HCM) family.6 Phenotypical features and DMPK [CTG]n 3′-untranslated region-repeat expansion in Family-1–Family-3. (A) Pedigrees showing DMPK 3′-untranslated region [CTG]n repeat genotypes in Family-1–Family-3 and MYL3 c.235G > A; p.(Val79Ile), variant of uncertain significance, in Family-1. Red indicates expanded DMPK 3′-untranslated region-CTG repeats; black indicates normal range. Family-1: the father’s (I-1) DNA was isolated from formalin-fixed paraffin-embedded tissue and was of insufficient quality to perform long-read sequencing; Family-1 subjects II-1 and II-2, *indicates no DNA available, and subject II-4, DNA was isolated from a peripheral blood sample at age 38, showing somatic expansion of the repeat length with age. Types of sequencing technology are depicted: triplet repeat-primed PCR, short-read sequencing, and long-read sequencing. MYL3: NM_000258.3:c.235G > A; p.(Val79Ile): ClinGen classification for MYL3 indicates a definitive association with hypertrophic cardiomyopathy and a limited association with arrhythmogenic cardiomyopathy. Andersen et al.6 reported MYL3 p.(Val79Ile) in an hypertrophic cardiomyopathy proband; among nine heterozygous family members, three exhibited borderline hypertrophic cardiomyopathy, while five younger carriers (ages 3–23 years) were asymptomatic. The variant has a minor allele frequency of 0.0088% in gnomAD v4.1.0 and a REVEL score of 0.49 (uncertain). American College of Medical Genetics and Genomics (ACMG) criterion PM2_Supportive is met. Overall classification: variant of uncertain significance. (B) Summary of electrocardiogram and cardiac MRI findings: electrocardiogram interpretations: Family-1 (I-1): abnormal electrocardiogram with left bundle branch block, PR-interval upper normal range. Normal-looking repolarization but prolonged corrected QT-interval, which is likely predominantly related to left bundle branch block, causing a prolonged QRS-interval. No advanced atrio-ventricular (AV) block/arrhythmia on Holter. Family-1 (II-3): Serial electrocardiograms showed corrected QT-interval ≤ 470 ms with normal PR-intervals and no evidence of progressive conduction disease. Holter monitoring and exercise testing shortly before sudden cardiac death were normal, with appropriate QT adaptation and no ventricular ectopy. Family-1 (II-4): sinus tachycardia abruptly progressed to likely supraventricular tachycardia, triggering implantable cardioverter-defibrillator shock, followed by 21 beats of tachycardia of indeterminate origin at 300 beats per minute. This was followed by two episodes of non-sustained ventricular tachycardia of seven and 14 beats, respectively. Family-1 (II-5): a single electrocardiogram demonstrated corrected QT-interval prolongation to 500 ms, prompting beta-blocker therapy. Serial electrocardiograms (ages 6–13 years), exercise testing, and Holter monitoring showed stable PR-interval (145–170 ms) and QRS (90–100 ms) intervals, corrected QT-interval of 430–500 ms, normal exercise-related QT adaptation, no ventricular ectopy, and a normal Holter 2 years prior to death. (C) Family-1 myotonic dystrophy Type 1 (DM1) phenotype. y.o., year old; d., died; SCD, unexplained sudden cardiac death; DM1, myotonic dystrophy Type 1; ICD, implantable cardioverter-defibrillator; RV, right ventricle; LV, left ventricle; TP, triplet repeat-primed PCR; SR, short-read sequencing (Illumina technology); LR, long-read sequencing (Oxford Nanopore Technology); QTc, corrected QT-interval; LBBB, left bundle branch block; VT, ventricular tachycardia; RVOT, right ventricular outflow tract; LGE, late gadolinium enhancement. The male proband (II-1) had witnessed SCD during endurance exercise at age 27. His 604 g heart showed patchy interstitial fibrosis with hypertrophic cardiomyocytes, and no cause of death was determined. Exome sequencing of 59 cardiac genes found no pathogenic variant. His nephew (III-1) died at 4 days with a clinical diagnosis of congenital DM1. Triplet-primed PCR identified a DMPK 3′UTR-repeat expansion in the nephew (III-1, >1400 repeats), his mother (II-2, >150), the proband (II-1, >120), and the proband’s father (I-1, >60) (Figure 1A and B). The male proband died suddenly at age 16 during exercise. His 405 g heart showed left ventricular lymphocytic inflammation and a septal thickness of 15 mm, and no cause of death was determined. Vis

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.